GlassScriptPhysician profile
Allison L Quist
NPI 1245836840
$1,796.05
in general payments reported to CMS, 2019-2025
33 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $560 · 2024: $956 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.69 | 2023-2025 | |
| Lilly USA, LLC | $154.49 | 2023-2024 | Mounjaro, Zepbound, Verzenio |
| Novartis Pharmaceuticals Corporation | $153.20 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2022 | |
| Janssen Biotech, INC. | $114.90 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $106.97 | 2023-2024 | Fruzaqla, Ninlaro |
| Merck Sharp & Dohme LLC | $99.59 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $77.72 | 2023-2024 | Monjuvi, Pemazyre, Jakafi |
| Stemline Therapeutics INC. | $59.71 | 2023-2024 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $58.31 | 2023-2025 | Enhertu, Calquence, Airsupra |
| Alexion Pharmaceuticals, INC. | $52.31 | 2024 | Ultomiris, Strensiq |
| Exelixis INC. | $49.43 | 2023-2024 | Cabometyx |
| Bausch Health US, LLC | $47.96 | 2024 | Aplenzin |
| Sobi, INC | $45.31 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.01 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.44 | 2023 | Injectafer, Enhertu |
| Genzyme Corporation | $37.04 | 2023-2024 | |
| Exact Sciences Corporation | $30.65 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $26.63 | 2023 | |
| Tempus Ai, INC | $24.93 | 2024 | |
| Eisai INC. | $23.72 | 2024 | |
| Tersera Therapeutics LLC | $23.68 | 2023 | Zoladex |
| Genentech USA, INC. | $23.14 | 2024 | Perjeta, Phesgo, Kadcyla |
| Genmab U.S., INC. | $22.39 | 2023 | Epkinly |
| Servier Pharmaceuticals LLC | $22.19 | 2024 | |
| Dendreon Pharmaceuticals LLC | $21.68 | 2023 | Provenge |
| Apellis Pharmaceuticals, INC. | $21.41 | 2023 | Empaveli |
| Indivior INC. | $18.63 | 2025 | Sublocade |
| Mirati Therapeutics, INC. | $18.27 | 2024 | Krazati |
| Recordati_rare_diseases_inc. | $17.30 | 2024 | Sylvant |
| Kyowa Kirin, INC. | $16.07 | 2023 | Poteligeo |
| Novo Nordisk INC | $15.38 | 2024 | Wegovy |
| Glaxosmithkline, LLC. | $14.16 | 2024 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Quist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.